Former President Trump doubled-down on his prior comments calling Democrats the "enemy from within" during a Fox News town hall in front of a women-only audience that aired Wednesday.
Why it matters: With less than three weeks until Election Day, Trump is seeking to boost his appeal among women voters, as polling shows that Vice President Kamala Harris has a clear advantage over this key bloc.
The Food and Drug Administration halted Novavax's trial of a combination vaccine for COVID and influenza, as well as a standalone flu shot, after a participant suffered a serious adverse event, the company said on Wednesday.
Why it matters: It's the latest setback for the company creating alternatives to mRNA vaccines in the race to make combination shots that include protection against the flu.
Alchemy, a developer of in-house pharmacy programs for clinics with large HIV and hepatitis C patient populations, raised $31 million in seed funding led by Andreessen Horowitz.
Why it matters: Antiretrovirals are one of biotech's greatest success stories, but there still are disparities in who receives the drugs.
Some private equity firms are pulling back from investing in consumer companies that could be negatively impacted by the GLP-1 boom, believing that profits will get squeezed as obesity rates fall.
Zoom in: That could include certain snackmakers, alcohol producers, or restaurant chains. Or gyms. Or grocery, which earns much of its meager margin on items that many GLP-1 users no longer crave.
The Democratic National Committee is blanketing the battlegrounds with billboards hitting former President Trump over reproductive rights, tying him to the abortion bans that have been linked to some women's deaths.
Why it matters: The billboards come before Trump's Fox News' town hall in front of a women-only audience is set to airas he seeks to appeal to a key demographic where Vice President Harris has a clear advantage.
GlaxoSmithKline is suing Moderna for allegedly using technology patented by GSK in its COVID-19 vaccine.
Why it matters: It's the latest in a series of legal fights over who owns the intellectual property behind mRNA technology and whether some companies are entitled to royalties on future sales.
Firstborn and only children are likelier to develop anxiety and depression by the time they reach age 8 than children who are born second or later, according to a new review of almost 182,500 cases.
Why it matters: The findings add another wrinkle to the still-unresolved debate over whether birth order affects childhood mental health. A conclusive link could aid in identifying other risk factors for behavioral disorders.
More than half of independent pharmacies are considering not stocking the first 10 drugs that were subject to Medicare price negotiations over concerns they'll have to absorb upfront costs.
Why it matters: If the drug stores decide it's not worth it to carry these drugs, seniors could have a harder time benefiting from the first round of reduced drug prices that take effect in 2026 — especially as more chain pharmacies close.
Walgreens is dramatically shrinking its retail footprint and revamping its front-of-store product mix in a bid to fend off competition from online and other rivals who've upended the pharmacy business.
Why it matters: The moves announced on Tuesday reflect big chain pharmacies' challenge to revive their core businesses amid sluggish demand, workforce crunches and shrinking prescription payments.
Walgreens Boots Alliance plans to close about 1,200 stores, representing roughly 10% of its locations worldwide.
Why it matters: CVS, Walgreens and Rite Aid long held a tight grip over prescription fulfillment, but they're losing their footing to a multitude of competitors, including mail-in options, online pharmacies and big-box stores.
Medicare could be throwing away as much as $336 million worth of a costly Alzheimer's drug each year because the size of vials is too big, UCLA researchers estimate.
Why it matters: The findings, published Monday in JAMA Internal Medicine,add to questions around the coverage of Leqembi, an infusable $26,500-a-year drug that's only available in single-use 500- and 200-milligram vials.
Back-to-back superstorms have tested health systems' ability to turn tabletop crisis exercises into reality on a dime as they raced to keep their facilities operational in the face of dangerous storm surges.
Why it matters: They largely passed the test. But the one-two punch of Hurricanes Helene and Milton exposed the need for better preparations and costly infrastructure upgrades.
Former President Trump is facing more calls to release his medical records after 238 doctors and other medical professionals joined Vice President Kamala Harris in calling on him to be "transparent" about his health.
Why it matters: The 78-year-old Republican presidential nominee would be the oldest president in U.S. history by the end of his term if he were to win November's election but, unlike 59-year-old Harris, he has yet to publicly release updated medical records.
